NCT00580047View on ClinicalTrials.gov

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

NACompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 1, 2003

Primary Completion Date

July 29, 2014

Study Completion Date

July 29, 2014

Conditions
Renal Insufficiency
Interventions
DRUG

Zoledronic Acid

4mg IV Annually

COMBINATION_PRODUCT

Calcium with vitamin D

1200 mg Calcium with 800 International Units of vitamin D

DRUG

Alendronate

70mg weekly

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER

NCT00580047 - Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants | Biotech Hunter | Biotech Hunter